Soligenix Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SoligenixDer Gewinn des Unternehmens wird voraussichtlich um 14.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 10.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 17.9% pro Jahr wachsen.

Wichtige Informationen

-11.0%

Wachstumsrate der Gewinne

57.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	36.7%
Wachstumsrate der Einnahmen	27.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0A6I - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-9	N/A	N/A	2
12/31/2025	1	-9	N/A	N/A	2
12/31/2024	1	-8	N/A	N/A	2
6/30/2024	0	-7	-8	-8	N/A
3/31/2024	1	-7	-8	-8	N/A
12/31/2023	1	-6	-9	-9	N/A
9/30/2023	1	-8	-10	-10	N/A
6/30/2023	1	-10	-11	-11	N/A
3/31/2023	1	-10	-12	-12	N/A
12/31/2022	1	-14	-13	-13	N/A
9/30/2022	1	-15	-12	-12	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-15	-11	-11	N/A
12/31/2021	1	-13	-12	-12	N/A
9/30/2021	1	-13	-13	-13	N/A
6/30/2021	1	-12	-13	-13	N/A
3/31/2021	2	-12	-13	-13	N/A
12/31/2020	2	-18	-11	-11	N/A
9/30/2020	3	-15	-10	-10	N/A
6/30/2020	3	-16	-9	-9	N/A
3/31/2020	4	-15	-8	-8	N/A
12/31/2019	5	-9	-8	-8	N/A
9/30/2019	5	-10	-8	-8	N/A
6/30/2019	5	-9	-6	-6	N/A
3/31/2019	5	-8	-8	-8	N/A
12/31/2018	5	-9	-7	-7	N/A
9/30/2018	6	-8	-7	-7	N/A
6/30/2018	6	-7	-7	-7	N/A
3/31/2018	5	-8	N/A	-6	N/A
12/31/2017	5	-7	N/A	-7	N/A
9/30/2017	6	-5	N/A	-6	N/A
6/30/2017	7	-6	N/A	-6	N/A
3/31/2017	9	-4	N/A	-6	N/A
12/31/2016	10	-3	N/A	-5	N/A
9/30/2016	12	-5	N/A	-5	N/A
6/30/2016	13	-1	N/A	-4	N/A
3/31/2016	11	-4	N/A	-5	N/A
12/31/2015	9	-8	N/A	-5	N/A
9/30/2015	8	-4	N/A	-4	N/A
6/30/2015	7	-11	N/A	-5	N/A
3/31/2015	7	-8	N/A	-4	N/A
12/31/2014	7	-7	N/A	-2	N/A
9/30/2014	6	-8	N/A	-3	N/A
6/30/2014	4	-10	N/A	-4	N/A
3/31/2014	3	-12	N/A	-4	N/A
12/31/2013	3	-10	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0A6I wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0A6I wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0A6I wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0A6IDie Einnahmen des Unternehmens (10.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0A6IDie Einnahmen des Unternehmens (20.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0A6I in 3 Jahren voraussichtlich hoch sein wird

Soligenix Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023)

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023)

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022)

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Insufficient new directors

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022)

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022)

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Insufficient new directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken